The CDMO wants to respond to the “Growing demand for biotherapeutics. “
The Japanese group, through its subsidiary Fujifilm Diosynth Biotechnologies, has announced an investment of $ 850 million (€ 718 million) to increase its development and production capacities for biological products.
Initially, the manufacturer intends to double its production of cell cultures, intended[…]
–
